

Our Ref: 201/2023  
APRIL 2023

## Re: Your request made under the Freedom of Information Act 2000

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] - 13
- Adalimumab [Humira] - 26
- Adalimumab Biosimilars - 367
- Apremilast [Otezla] - 1
- Baricitinib [Olumiant] - 54
- Certolizumab [Cimzia] - 16
- Etanercept [Enbrel] - 3
- Etanercept Biosimilars - 169
- Filgotinib [Jyseleca] - 35
- Golimumab [Simponi] - 42
- Guselkumab [Tremfya] - 2
- Infliximab [Remicade] - 0
- Infliximab Biosimilars - 24
- Ixekizumab [Taltz] - 6
- Risankizumab [Skyrizi] - 0
- Rituximab [MabThera] - 0
- Rituximab Biosimilars - 27
- Sarilumab [Kevzara] - 5
- Secukinumab [Cosentyx] - 39
- Tocilizumab [Ro Actemra] - 28
- Tofacitinib [Xeljanz] - 6
- Upadacitinib [Rinvoq] - 20
- Ustekinumab [Stelara] - 5